ClinicalTrials.gg
CompletedNCT01284634Updated Aug 8, 2018Results posted

Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

A Phase 2 interventional study of GWP42003 200 mg/day Dose and GWP42003 400 mg/day Dose in Fatty Liver, sponsored by GW Research Ltd. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by GW Research Ltd (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies in Fatty Liver with a site in United Kingdom — 16 open to participants now, 19 under way, 4 of them phase 3. Fatty Liver · United Kingdom.

Enrollment
27th of 34
25 · median 81
Started
2011
with 2 others
Phase 2
9 of 44
1 open now
Registered
5th of 44
by date

Among the 44 studies in Fatty Liver with a site in United Kingdom, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 5th registered.

Fatty Liver

664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

16 of the 44 studies in Fatty Liver with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Fatty Liver with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).

Read the detailed description

This study was conducted as a 10-week (eight-week treatment period and one-week safety follow-up), randomized, partially-blind study that evaluated the effect of GWP42003 in participants with raised liver triglycerides (liver fat ≥5%). Participants were clinically diagnosed with FLD and had liver fat levels ≥5% as measured by Magnetic Resonance Imaging/ Magnetic Resonance Scanning (MRI/MRS), or were willing to undergo MRI/MRS scan at the screening visit to confirm a liver fat content of ≥5%. Eligible participants entered the study at a screening visit (Day -10 to -2) and then returned for a fasted baseline visit (Day 1), a mid-treatment visit (Day 29) and an end of treatment visit (Day 57). Safety follow-up telephone calls took place throughout the treatment period up to Day 64 after completion of treatment or seven days after date of last dose/withdrawal.

03

Conditions studied

  • Fatty Liver

Keywords

  • Cannabidiol
  • Fatty liver
  • Diabetes
  • Body fat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant gave for participation in the study.
  • Participant was aged 18 years or above.
  • Participant had documented evidence of liver fat content ≥5% as measured by MRI/MRS scanning or a within two months prior to screening, or willing to undergo an MRI/MRS scan at Visit 1 (Day -10 to -2) to confirm a liver fat content of ≥5%.
  • Participant had, in the opinion of the investigator, no changes in levels of exercise or diet for four weeks (as assessed by the physical activity questionnaire and food frequency questionnaire) prior to the start of treatment, and participant agreed to keep stable for the duration of the study.
  • Participant was able (in the investigator's opinion) and willing to comply with all study requirements.
  • Participant was willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable.
  • Participant was willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Participant had clinical diagnosis or treatment for Type I/II diabetes.
  • Participant had received an unapproved medicinal product (IMP) within the 30 days prior to the screening visit.
  • Participant was receiving a prohibited medication and unwilling to stop for 14 days prior to the screening visit and for the duration of the study.
  • Participant was using or had used recreational cannabis, medicinal cannabis, or cannabinoid medications (including Sativex) within one month prior to study entry and unwilling to abstain for the duration of the study.
  • Participant had any known or suspected history of alcohol or substance abuse, or epilepsy or recurrent seizures.
  • Participant had any known or suspected history of major depression sufficient to require treatment or disrupt ordinary life (excluding episodes of reactive depression, in the opinion of the investigator).
  • Participant had cardiac, renal, or hepatic impairment, in the opinion of the investigator.
  • Participant had known history of or C.
  • Participant had genetic dyslipidaemia, in the opinion of the Investigator.
  • Participant had any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, influence the result of the study, or affect the participant's ability to participate in the study.
  • Participant had any known or suspected to cannabinoids or any of the of the IMP(s).
  • Participant had presence of any metal implants.
  • Participant had any known or suspected history of claustrophobia.
  • Female participants of child bearing potential not able or willing to use effective for the duration of the study and for three months thereafter, or male participants whose partner was of child bearing potential, who was not willing to ensure that they or their partner would use effective contraception during the study and for three months thereafter.
  • Female participant who was pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
  • Participants who weighed >150 kilograms (kg).
  • Participant had any abnormalities following a physical examination that, in the opinion of the investigator, prevented the participant from safe participation in the study.
  • Participant was unwilling to abstain from donation of blood during the study.
  • Participant had planned travel outside the country of residence during the study.
  • Participant had previously enrolled into this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    GWP42003 200 milligrams (mg)/day Dose

    Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).

    Drug: GWP42003 200 mg/day Dose

  • Experimental
    GWP42003 400 mg/day Dose

    Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).

    Drug: GWP42003 400 mg/day Dose

  • Experimental
    GWP42003 800 mg/day Dose

    Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).

    Drug: GWP42003 800 mg/day Dose

  • Experimental
    Placebo

    Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.

    Drug: Placebo

Interventions

  • DrugGWP42003 200 mg/day Dose

    Drug page: Cannabidiol

    GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

    Also known as: Cannabidiol, CBD

  • DrugGWP42003 400 mg/day Dose

    Drug page: Cannabidiol

    GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

    Also known as: Cannabidiol, CBD

  • DrugGWP42003 800 mg/day Dose

    Drug page: Cannabidiol

    GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

    Also known as: Cannabidiol, CBD

  • DrugPlacebo

    Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).

    Also known as: Placebo control

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels

    Liver triglyceride levels were measured by Magnetic Resonance Imaging/Magnetic Resonance Scanning and the percent change from baseline to EOT in group mean levels was investigated. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or Early Termination (ET)

Secondary outcomes

  1. Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels

    A fasting blood sample was taken for the measurement of serum total cholesterol. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or ET

  2. Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels

    A fasting blood sample was obtained for the measurement of HDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or ET

  3. Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels

    A fasting blood sample was obtained for the measurement of LDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or ET

  4. Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio

    A fasting blood sample was obtained for the measurement of HDL-C and LDL-C, allowing the HDL:LDL cholesterol ratio to be calculated. An increase from baseline, that is, a positive value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or ET

  5. Change From Baseline To The EOT In Mean Serum Triglyceride Levels

    A fasting blood sample was obtained for the measurement of serum triglycerides. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

    Time frame: Baseline to EOT (Day 57) or ET

07

Results

Posted Jan 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneGWP42003 200 Milligram (mg)/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Started7675
Received at least 1 dose of study drug7675
Intent to treat (itt) analysis set7675
Completed6654
Not completed1021
Withdrew: Adverse event1021

Outcome measures

PrimaryPercent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels

Liver triglyceride levels were measured by Magnetic Resonance Imaging/Magnetic Resonance Scanning and the percent change from baseline to EOT in group mean levels was investigated. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or Early Termination (ET)
Reported as:
Mean · percentage change
Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels
percentage changeGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels-0.68 ± 4.97-0.28 ± 8.600.65 ± 5.286.36 ± 17.97
Statistical analysis
  • GWP42003 200 mg/Day Dose vs Placebo · Regression, Linear · p = 0.222 · Mean difference (final values): -6.89 · 90% CI -16.35 to 2.56
  • GWP42003 400 mg/Day Dose vs Placebo · Regression, Linear · p = 0.133 · Mean difference (final values): -9.35 · 90% CI -19.66 to 0.95
  • GWP42003 800 mg/Day Dose vs Placebo · Regression, Linear · p = 0.302 · Mean difference (final values): -6.54 · 90% CI -17.22 to 4.14
SecondaryChange From Baseline To The EOT In Mean Serum Total Cholesterol Levels

A fasting blood sample was taken for the measurement of serum total cholesterol. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or ET
Reported as:
Mean · millimole (mmol)/l
Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels
millimole (mmol)/lGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels0.07 ± 0.760.03 ± 0.51-0.14 ± 0.31-0.62 ± 1.00
SecondaryChange From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels

A fasting blood sample was obtained for the measurement of HDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or ET
Reported as:
Mean · mmol/l
Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels
mmol/lGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels0.07 ± 0.150.08 ± 0.150.06 ± 0.17-0.14 ± 0.23
SecondaryChange From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels

A fasting blood sample was obtained for the measurement of LDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or ET
Reported as:
Mean · mmol/l
Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels
mmol/lGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels0.11 ± 0.6310.08 ± 0.4070.00 ± 0.432-0.34 ± 0.737
SecondaryChange From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio

A fasting blood sample was obtained for the measurement of HDL-C and LDL-C, allowing the HDL:LDL cholesterol ratio to be calculated. An increase from baseline, that is, a positive value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or ET
Reported as:
Mean · change in ratio
Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio
change in ratioGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio-0.02 ± 0.13-0.00 ± 0.080.03 ± 0.090.01 ± 0.06
SecondaryChange From Baseline To The EOT In Mean Serum Triglyceride Levels

A fasting blood sample was obtained for the measurement of serum triglycerides. A reduction from baseline, that is, a negative value, indicates an improvement in condition.

Time frame:
Baseline to EOT (Day 57) or ET
Reported as:
Mean · mmol/l
Change From Baseline To The EOT In Mean Serum Triglyceride Levels
mmol/lGWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlacebo
Change From Baseline To The EOT In Mean Serum Triglyceride Levels-0.40 ± 1.05-0.29 ± 0.82-0.50 ± 1.16-0.28 ± 0.39

Adverse events

Collected over Day 1 through Day 77. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003 200 mg/Day Dose—0/7 (0%)6/7 (85.7%)
GWP42003 400 mg/Day Dose—0/6 (0%)5/6 (83.3%)
800 mg GWP42003—0/7 (0%)7/7 (100%)
Placebo—0/5 (0%)5/5 (100%)
Most frequent other events
Showing 10 of 50
Most frequent other events
EventGWP42003 200 mg/Day DoseGWP42003 400 mg/Day Dose800 mg GWP42003Placebo
DiarrhoeaGastrointestinal disorders4/73/65/70/5
HeadacheNervous system disorders1/73/62/70/5
Abdominal distensionGastrointestinal disorders0/71/61/71/5
Abdominal painGastrointestinal disorders0/71/61/71/5
Abnormal faecesGastrointestinal disorders0/70/60/71/5
Change of bowel habitGastrointestinal disorders0/70/60/71/5
ConstipationGastrointestinal disorders0/70/60/71/5
FlatulenceGastrointestinal disorders0/70/60/71/5
NauseaGastrointestinal disorders1/71/60/71/5
Seasonal allergyImmune system disorders0/71/60/71/5

Baseline characteristics

Safety Analysis Set: Participants who received at least 1 dose of investigational medicinal product (IMP); analyzed as per actual treatment received.

Age, Continuous
Age, Continuous(years)GWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlaceboTotal
Mean40.69 ± 14.6249.08 ± 7.7246.90 ± 12.5750.41 ± 18.4146.39 ± 13.29
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003 200 mg/Day DoseGWP42003 400 mg/Day DoseGWP42003 800 mg/Day DosePlaceboTotal
Female522413
Male245112
08

Study locations

3 sites
  • London, W120NN, United Kingdom
  • Manchester, M13 9WL, United Kingdom
  • Manchester, M32 0UT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Jul 2012, 14 months.

Results were first posted in Jan 2014, 1 year 6 months after primary completion.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2011
First posted
Jan 27, 2011
StartActual
May 3, 2011
Primary completionActual
Jul 13, 2012
CompletionActual
Jul 13, 2012
Results first posted
Jan 20, 2014
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01284634
Lead sponsor
GW Research Ltd
Responsible party
Sponsor
First posted
Jan 27, 2011
Start date
May 3, 2011
Primary completion
Jul 13, 2012
Completion
Jul 13, 2012
Results posted
Jan 20, 2014
Last update
Aug 8, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion